Daniel Spasic

Daniel Spasic serves as the Executive Chairman of Julius Clinical, a scientific clinical CRO specializing in CNS, cardiometabolic, and renal indications, since November 2023. Spasic holds multiple board positions, including Non-Executive Board Member at PathoQuest, iuvo BioScience, Avance Clinical, Scantox, NuvoAir, and Trialbee, alongside a previous role at Proteros biostructures. Additionally, Spasic is the Chairman of the Board at Inhalation Sciences Sweden AB and operates as a life science entrepreneur and growth advisor through S-Growth Advisors LLC. Educational credentials include completion of the Owner/President Management Program at Harvard Business School and military training with the Swedish Armed Forces.